financetom
Business
financetom
/
Business
/
BitMine Immersion Stock Shoots Higher On Ethereum Rally
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BitMine Immersion Stock Shoots Higher On Ethereum Rally
Aug 22, 2025 2:16 PM

BitMine Immersion Technologies Inc. ( BMNR ) shares climbed on Friday as markets rallied following dovish remarks from Federal Reserve Chair Jerome Powell.  

BMNR stock rocketed higher.  See the chart here. 

Crypto Explodes Higher

Cryptocurrencies soared after Powell hinted at possible interest rate cuts, fueling optimism across digital assets. 

Ethereum (CRYPTO: ETH) was up 14% and Bitcoin (CRYPTO: BTC) rose 3.76% at the time of publication Friday. 

See Also: President Trump Worth More Than $5.5 Billion After $100 Million In Bond Purchases While In Office

BitMine on Monday announced that its crypto holdings now consist of approximately 1.52 million ETH and 192 Bitcoin, making it the largest Ethereum treasury company and second-largest global crypto strategy behind Strategy

The company's ETH holdings were up more than 373,000 since BitMine reported total holdings valued at $4.96 billion last week.

"In just a week, BitMine increased its ETH holdings by $1.7 billion to $6.6 billion (adding over 373,000 tokens from 1.15 million to 1.52 million tokens), as institutional investors have expressed interest and support for our pursuit of the ‘alchemy of 5%' of ETH," said Tom Lee, chairman of BitMine.

Friday's ETH rally, triggered by risk-on sentiment and a rebound above $4,650, directly increased BMNR's asset value and attracted bullish investors. 

Options activity also rose sharply on Friday, with aggressive call buying as traders positioned for further gains. BitMine's options volume was more than double the daily average with 348,000 contracts traded and calls leading puts for a put/call ratio of 0.33, according to The Fly. 

BMNR Stock Price

BitMine Immersion ( BMNR ) shares ended Friday's session 12.07% higher at $53.49, according to data from Benzinga Pro. BMNR stock has gained more than 32% over the past month. 

Read Next: 

Opendoor CEO Embraces AI And Retail Investors: ‘Thanks For Believing’

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition
Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition
Aug 12, 2024
03:45 PM EDT, 08/12/2024 (MT Newswires) -- (Updates to reflect Eli Lilly ( LLY ) declined comment to MT Newswires) Eli Lilly ( LLY ) filed a prospectus Monday to raise debt for its $3.2 billion acquisition of Morphic. According to a securities filing, the pharma company is looking to issue five separate series of notes to raise $5 billion...
Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing
Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing
Aug 12, 2024
03:56 PM EDT, 08/12/2024 (MT Newswires) -- Michael Osanloo, Director, President & CEO, on August 09, 2024, sold 66,052 shares in Portillo's (PTLO) for $679,675. Following the Form 4 filing with the SEC, Osanloo has control over a total of 79,041 shares of the company, with 79,041 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1871509/000187150924000105/xslF345X03/wk-form4_1723492418.xml Price: 10.82, Change: +0.11, Percent Change: +1.03...
Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss
Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss
Aug 12, 2024
03:45 PM EDT, 08/12/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) shares were down nearly 8% in recent Monday trading after the company reported a wider-than-expected Q2 net loss. The company reported a Q2 net loss of $0.33 per diluted share, compared with a loss of $0.46 a year earlier. Analysts polled by Capital IQ expected a $0.18 loss....
Novartis loses initial bid to block generic of best-selling heart drug
Novartis loses initial bid to block generic of best-selling heart drug
Aug 12, 2024
Aug 12 (Reuters) - Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday. U.S. District Judge Richard Andrews ruled that Novartis' chance of winning its patent-infringement lawsuit challenging the generic was too low to justify halting...
Copyright 2023-2026 - www.financetom.com All Rights Reserved